64Cu-DOTAGA-alphaCD276 mAb (Provenance/University Hospital Tubingen/University Children's Hospital Tuebingen)

N/A

Report date: 2025/01/26 19:15:46

Base Information

Drug Name64Cu-DOTAGA-alphaCD276 mAb (Provenance/University Hospital Tubingen/University Children's Hospital Tuebingen)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateRadiation-emitting products
Mechanisms of ActionCD276 antigen modulators
TargetsCD276 antigen
Therapy Area/IndicationsNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesProvenance Biopharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesProvenance BiopharmaceuticalsUniversity Children'S Hospital TuebingenUniversity Hospital Tubingen
Inactive CompaniesN/A
Active IndicationsNeuroblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A